Pharma & Healthcare
Global Respiratory Syncytial Virus Vaccine for the Elderly Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 04, 25
- ID: 562826
- Pages: 167
- Figures: 156
- Views: 3
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Respiratory Syncytial Virus Vaccine for the Elderly market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
GSK
Pfizer
Moderna
Daiichi Sankyo
Icosavax
Sanofi
Blue Lake Biotechnology
Advaccine
Starna Therapeutics
Immorna
Clover Biopharma
Innorna
RNAimmune
Segment by Type
Recombinant Protein Vaccine
Nucleic Acid Vaccines
Others
Segment by Application
Hospital
Centers for Disease Control and Prevention
Others
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Respiratory Syncytial Virus Vaccine for the Elderly study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Respiratory Syncytial Virus Vaccine for the Elderly market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
GSK
Pfizer
Moderna
Daiichi Sankyo
Icosavax
Sanofi
Blue Lake Biotechnology
Advaccine
Starna Therapeutics
Immorna
Clover Biopharma
Innorna
RNAimmune
Segment by Type
Recombinant Protein Vaccine
Nucleic Acid Vaccines
Others
Segment by Application
Hospital
Centers for Disease Control and Prevention
Others
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Respiratory Syncytial Virus Vaccine for the Elderly study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Respiratory Syncytial Virus Vaccine for the Elderly: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Recombinant Protein Vaccine
1.2.3 Nucleic Acid Vaccines
1.2.4 Others
1.3 Market Segmentation by Application
1.3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Centers for Disease Control and Prevention
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Estimates and Forecasts 2020-2031
2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Estimates and Forecasts 2020-2031
2.4 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Recombinant Protein Vaccine Market Size by Manufacturers
3.5.2 Nucleic Acid Vaccines Market Size by Manufacturers
3.5.3 Others Market Size by Manufacturers
3.6 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales and Revenue by Type (2020-2031)
6.4 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales and Revenue by Type (2020-2031)
7.4 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Respiratory Syncytial Virus Vaccine for the Elderly Sales and Revenue by Type (2020-2031)
9.4 Central and South America Respiratory Syncytial Virus Vaccine for the Elderly Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 GSK
11.1.1 GSK Corporation Information
11.1.2 GSK Business Overview
11.1.3 GSK Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.1.4 GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales by Product in 2024
11.1.6 GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application in 2024
11.1.7 GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales by Geographic Area in 2024
11.1.8 GSK Respiratory Syncytial Virus Vaccine for the Elderly SWOT Analysis
11.1.9 GSK Recent Developments
11.2 Pfizer
11.2.1 Pfizer Corporation Information
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.2.4 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales by Product in 2024
11.2.6 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application in 2024
11.2.7 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales by Geographic Area in 2024
11.2.8 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly SWOT Analysis
11.2.9 Pfizer Recent Developments
11.3 Moderna
11.3.1 Moderna Corporation Information
11.3.2 Moderna Business Overview
11.3.3 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.3.4 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales by Product in 2024
11.3.6 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application in 2024
11.3.7 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales by Geographic Area in 2024
11.3.8 Moderna Respiratory Syncytial Virus Vaccine for the Elderly SWOT Analysis
11.3.9 Moderna Recent Developments
11.4 Daiichi Sankyo
11.4.1 Daiichi Sankyo Corporation Information
11.4.2 Daiichi Sankyo Business Overview
11.4.3 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.4.4 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales by Product in 2024
11.4.6 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application in 2024
11.4.7 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales by Geographic Area in 2024
11.4.8 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly SWOT Analysis
11.4.9 Daiichi Sankyo Recent Developments
11.5 Icosavax
11.5.1 Icosavax Corporation Information
11.5.2 Icosavax Business Overview
11.5.3 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.5.4 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales by Product in 2024
11.5.6 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application in 2024
11.5.7 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales by Geographic Area in 2024
11.5.8 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly SWOT Analysis
11.5.9 Icosavax Recent Developments
11.6 Sanofi
11.6.1 Sanofi Corporation Information
11.6.2 Sanofi Business Overview
11.6.3 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.6.4 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Sanofi Recent Developments
11.7 Blue Lake Biotechnology
11.7.1 Blue Lake Biotechnology Corporation Information
11.7.2 Blue Lake Biotechnology Business Overview
11.7.3 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.7.4 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Blue Lake Biotechnology Recent Developments
11.8 Advaccine
11.8.1 Advaccine Corporation Information
11.8.2 Advaccine Business Overview
11.8.3 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.8.4 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Advaccine Recent Developments
11.9 Starna Therapeutics
11.9.1 Starna Therapeutics Corporation Information
11.9.2 Starna Therapeutics Business Overview
11.9.3 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.9.4 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Starna Therapeutics Recent Developments
11.10 Immorna
11.10.1 Immorna Corporation Information
11.10.2 Immorna Business Overview
11.10.3 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.10.4 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Immorna Recent Developments
11.11 Clover Biopharma
11.11.1 Clover Biopharma Corporation Information
11.11.2 Clover Biopharma Business Overview
11.11.3 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.11.4 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Clover Biopharma Recent Developments
11.12 Innorna
11.12.1 Innorna Corporation Information
11.12.2 Innorna Business Overview
11.12.3 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.12.4 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Innorna Recent Developments
11.13 RNAimmune
11.13.1 RNAimmune Corporation Information
11.13.2 RNAimmune Business Overview
11.13.3 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.13.4 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 RNAimmune Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Respiratory Syncytial Virus Vaccine for the Elderly Industry Chain
12.2 Respiratory Syncytial Virus Vaccine for the Elderly Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Respiratory Syncytial Virus Vaccine for the Elderly Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Respiratory Syncytial Virus Vaccine for the Elderly Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Respiratory Syncytial Virus Vaccine for the Elderly Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Respiratory Syncytial Virus Vaccine for the Elderly Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Respiratory Syncytial Virus Vaccine for the Elderly: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Recombinant Protein Vaccine
1.2.3 Nucleic Acid Vaccines
1.2.4 Others
1.3 Market Segmentation by Application
1.3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Centers for Disease Control and Prevention
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Estimates and Forecasts 2020-2031
2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Estimates and Forecasts 2020-2031
2.4 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Recombinant Protein Vaccine Market Size by Manufacturers
3.5.2 Nucleic Acid Vaccines Market Size by Manufacturers
3.5.3 Others Market Size by Manufacturers
3.6 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales and Revenue by Type (2020-2031)
6.4 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales and Revenue by Type (2020-2031)
7.4 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Respiratory Syncytial Virus Vaccine for the Elderly Sales and Revenue by Type (2020-2031)
9.4 Central and South America Respiratory Syncytial Virus Vaccine for the Elderly Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 GSK
11.1.1 GSK Corporation Information
11.1.2 GSK Business Overview
11.1.3 GSK Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.1.4 GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales by Product in 2024
11.1.6 GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application in 2024
11.1.7 GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales by Geographic Area in 2024
11.1.8 GSK Respiratory Syncytial Virus Vaccine for the Elderly SWOT Analysis
11.1.9 GSK Recent Developments
11.2 Pfizer
11.2.1 Pfizer Corporation Information
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.2.4 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales by Product in 2024
11.2.6 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application in 2024
11.2.7 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales by Geographic Area in 2024
11.2.8 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly SWOT Analysis
11.2.9 Pfizer Recent Developments
11.3 Moderna
11.3.1 Moderna Corporation Information
11.3.2 Moderna Business Overview
11.3.3 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.3.4 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales by Product in 2024
11.3.6 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application in 2024
11.3.7 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales by Geographic Area in 2024
11.3.8 Moderna Respiratory Syncytial Virus Vaccine for the Elderly SWOT Analysis
11.3.9 Moderna Recent Developments
11.4 Daiichi Sankyo
11.4.1 Daiichi Sankyo Corporation Information
11.4.2 Daiichi Sankyo Business Overview
11.4.3 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.4.4 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales by Product in 2024
11.4.6 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application in 2024
11.4.7 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales by Geographic Area in 2024
11.4.8 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly SWOT Analysis
11.4.9 Daiichi Sankyo Recent Developments
11.5 Icosavax
11.5.1 Icosavax Corporation Information
11.5.2 Icosavax Business Overview
11.5.3 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.5.4 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales by Product in 2024
11.5.6 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application in 2024
11.5.7 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales by Geographic Area in 2024
11.5.8 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly SWOT Analysis
11.5.9 Icosavax Recent Developments
11.6 Sanofi
11.6.1 Sanofi Corporation Information
11.6.2 Sanofi Business Overview
11.6.3 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.6.4 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Sanofi Recent Developments
11.7 Blue Lake Biotechnology
11.7.1 Blue Lake Biotechnology Corporation Information
11.7.2 Blue Lake Biotechnology Business Overview
11.7.3 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.7.4 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Blue Lake Biotechnology Recent Developments
11.8 Advaccine
11.8.1 Advaccine Corporation Information
11.8.2 Advaccine Business Overview
11.8.3 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.8.4 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Advaccine Recent Developments
11.9 Starna Therapeutics
11.9.1 Starna Therapeutics Corporation Information
11.9.2 Starna Therapeutics Business Overview
11.9.3 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.9.4 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Starna Therapeutics Recent Developments
11.10 Immorna
11.10.1 Immorna Corporation Information
11.10.2 Immorna Business Overview
11.10.3 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.10.4 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Immorna Recent Developments
11.11 Clover Biopharma
11.11.1 Clover Biopharma Corporation Information
11.11.2 Clover Biopharma Business Overview
11.11.3 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.11.4 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Clover Biopharma Recent Developments
11.12 Innorna
11.12.1 Innorna Corporation Information
11.12.2 Innorna Business Overview
11.12.3 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.12.4 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Innorna Recent Developments
11.13 RNAimmune
11.13.1 RNAimmune Corporation Information
11.13.2 RNAimmune Business Overview
11.13.3 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Product Models, Descriptions and Specifications
11.13.4 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 RNAimmune Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Respiratory Syncytial Virus Vaccine for the Elderly Industry Chain
12.2 Respiratory Syncytial Virus Vaccine for the Elderly Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Respiratory Syncytial Virus Vaccine for the Elderly Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Respiratory Syncytial Virus Vaccine for the Elderly Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Respiratory Syncytial Virus Vaccine for the Elderly Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Respiratory Syncytial Virus Vaccine for the Elderly Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Dose)
Table 7. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2020-2025) & (Dose)
Table 8. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2026-2031) & (Dose)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Manufacturers (2020-2025) & (Dose)
Table 11. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Share by Manufacturers (2020-2025)
Table 12. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Respiratory Syncytial Virus Vaccine for the Elderly by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Syncytial Virus Vaccine for the Elderly as of 2024)
Table 16. Global Respiratory Syncytial Virus Vaccine for the Elderly Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Respiratory Syncytial Virus Vaccine for the Elderly Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Dose)
Table 18. Key Manufacturers Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base and Headquarters
Table 19. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2020-2025) & (Dose)
Table 23. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2026-2031) & (Dose)
Table 24. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Respiratory Syncytial Virus Vaccine for the Elderly ASP by Type (2020-2031) & (US$/Dose)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2020-2025) & (Dose)
Table 29. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2026-2031) & (Dose)
Table 30. Respiratory Syncytial Virus Vaccine for the Elderly High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Respiratory Syncytial Virus Vaccine for the Elderly ASP by Application (2020-2031) & (US$/Dose)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Respiratory Syncytial Virus Vaccine for the Elderly Growth Accelerators and Market Barriers
Table 37. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Respiratory Syncytial Virus Vaccine for the Elderly Growth Accelerators and Market Barriers
Table 40. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Growth Accelerators and Market Barriers
Table 45. Southeast Asia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Respiratory Syncytial Virus Vaccine for the Elderly Investment Opportunities and Key Challenges
Table 47. Central and South America Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. GSK Corporation Information
Table 51. GSK Description and Major Businesses
Table 52. GSK Product Models, Descriptions and Specifications
Table 53. GSK Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 54. GSK Sales Value Proportion by Product in 2024
Table 55. GSK Sales Value Proportion by Application in 2024
Table 56. GSK Sales Value Proportion by Geographic Area in 2024
Table 57. GSK Respiratory Syncytial Virus Vaccine for the Elderly SWOT Analysis
Table 58. GSK Recent Developments
Table 59. Pfizer Corporation Information
Table 60. Pfizer Description and Major Businesses
Table 61. Pfizer Product Models, Descriptions and Specifications
Table 62. Pfizer Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 63. Pfizer Sales Value Proportion by Product in 2024
Table 64. Pfizer Sales Value Proportion by Application in 2024
Table 65. Pfizer Sales Value Proportion by Geographic Area in 2024
Table 66. Pfizer Respiratory Syncytial Virus Vaccine for the Elderly SWOT Analysis
Table 67. Pfizer Recent Developments
Table 68. Moderna Corporation Information
Table 69. Moderna Description and Major Businesses
Table 70. Moderna Product Models, Descriptions and Specifications
Table 71. Moderna Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 72. Moderna Sales Value Proportion by Product in 2024
Table 73. Moderna Sales Value Proportion by Application in 2024
Table 74. Moderna Sales Value Proportion by Geographic Area in 2024
Table 75. Moderna Respiratory Syncytial Virus Vaccine for the Elderly SWOT Analysis
Table 76. Moderna Recent Developments
Table 77. Daiichi Sankyo Corporation Information
Table 78. Daiichi Sankyo Description and Major Businesses
Table 79. Daiichi Sankyo Product Models, Descriptions and Specifications
Table 80. Daiichi Sankyo Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 81. Daiichi Sankyo Sales Value Proportion by Product in 2024
Table 82. Daiichi Sankyo Sales Value Proportion by Application in 2024
Table 83. Daiichi Sankyo Sales Value Proportion by Geographic Area in 2024
Table 84. Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly SWOT Analysis
Table 85. Daiichi Sankyo Recent Developments
Table 86. Icosavax Corporation Information
Table 87. Icosavax Description and Major Businesses
Table 88. Icosavax Product Models, Descriptions and Specifications
Table 89. Icosavax Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 90. Icosavax Sales Value Proportion by Product in 2024
Table 91. Icosavax Sales Value Proportion by Application in 2024
Table 92. Icosavax Sales Value Proportion by Geographic Area in 2024
Table 93. Icosavax Respiratory Syncytial Virus Vaccine for the Elderly SWOT Analysis
Table 94. Icosavax Recent Developments
Table 95. Sanofi Corporation Information
Table 96. Sanofi Description and Major Businesses
Table 97. Sanofi Product Models, Descriptions and Specifications
Table 98. Sanofi Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 99. Sanofi Recent Developments
Table 100. Blue Lake Biotechnology Corporation Information
Table 101. Blue Lake Biotechnology Description and Major Businesses
Table 102. Blue Lake Biotechnology Product Models, Descriptions and Specifications
Table 103. Blue Lake Biotechnology Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 104. Blue Lake Biotechnology Recent Developments
Table 105. Advaccine Corporation Information
Table 106. Advaccine Description and Major Businesses
Table 107. Advaccine Product Models, Descriptions and Specifications
Table 108. Advaccine Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 109. Advaccine Recent Developments
Table 110. Starna Therapeutics Corporation Information
Table 111. Starna Therapeutics Description and Major Businesses
Table 112. Starna Therapeutics Product Models, Descriptions and Specifications
Table 113. Starna Therapeutics Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 114. Starna Therapeutics Recent Developments
Table 115. Immorna Corporation Information
Table 116. Immorna Description and Major Businesses
Table 117. Immorna Product Models, Descriptions and Specifications
Table 118. Immorna Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 119. Immorna Recent Developments
Table 120. Clover Biopharma Corporation Information
Table 121. Clover Biopharma Description and Major Businesses
Table 122. Clover Biopharma Product Models, Descriptions and Specifications
Table 123. Clover Biopharma Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 124. Clover Biopharma Recent Developments
Table 125. Innorna Corporation Information
Table 126. Innorna Description and Major Businesses
Table 127. Innorna Product Models, Descriptions and Specifications
Table 128. Innorna Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 129. Innorna Recent Developments
Table 130. RNAimmune Corporation Information
Table 131. RNAimmune Description and Major Businesses
Table 132. RNAimmune Product Models, Descriptions and Specifications
Table 133. RNAimmune Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 134. RNAimmune Recent Developments
Table 135. Key Raw Materials Distribution
Table 136. Raw Materials Key Suppliers
Table 137. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 138. Milestones in Production Technology Evolution
Table 139. Distributors List
Table 140. Market Trends and Market Evolution
Table 141. Market Drivers and Opportunities
Table 142. Market Challenges, Risks, and Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Respiratory Syncytial Virus Vaccine for the Elderly Product Picture
Figure 2. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Recombinant Protein Vaccine Product Picture
Figure 4. Nucleic Acid Vaccines Product Picture
Figure 5. Others Product Picture
Figure 6. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Hospital
Figure 8. Centers for Disease Control and Prevention
Figure 9. Others
Figure 10. Respiratory Syncytial Virus Vaccine for the Elderly Report Years Considered
Figure 11. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 13. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Region (2020-2031)
Figure 15. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (2020-2031) & (Dose)
Figure 16. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (CAGR) by Region (2020-2031) (Dose)
Figure 17. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Region (2020-2031)
Figure 18. Top 5 and Top 10 Manufacturers Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume Market Share in 2024
Figure 19. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. Recombinant Protein Vaccine Revenue Market Share by Manufacturer in 2024
Figure 22. Nucleic Acid Vaccines Revenue Market Share by Manufacturer in 2024
Figure 23. Others Revenue Market Share by Manufacturer in 2024
Figure 24. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2020-2031)
Figure 25. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2020-2031)
Figure 26. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2020-2031)
Figure 27. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application (2020-2031)
Figure 28. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales YoY (2020-2031) & (Dose)
Figure 29. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue YoY (2020-2031) & (US$ Million)
Figure 30. North America Top 5 Manufacturers Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) in 2024
Figure 31. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume (Dose) by Type (2020- 2031)
Figure 32. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 33. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume (Dose) by Application (2020-2031)
Figure 34. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) by Application (2020-2031)
Figure 35. US Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 36. Canada Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 37. Mexico Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 38. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales YoY (2020-2031) & (Dose)
Figure 39. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Europe Top 5 Manufacturers Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) in 2024
Figure 41. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume (Dose) by Type (2020-2031)
Figure 42. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) by Type (2020-2031)
Figure 43. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume (Dose) by Application (2020-2031)
Figure 44. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) by Application (2020-2031)
Figure 45. Germany Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 46. France Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 47. U.K. Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 48. Italy Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 49. Russia Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales YoY (2020-2031) & (Dose)
Figure 51. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Asia-Pacific Top 8 Manufacturers Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) in 2024
Figure 53. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume (Dose) by Type (2020- 2031)
Figure 54. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 55. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume (Dose) by Application (2020-2031)
Figure 56. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) by Application (2020-2031)
Figure 57. Indonesia Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 58. Japan Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 59. South Korea Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 60. China Taiwan Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 61. India Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 62. Central and South America Respiratory Syncytial Virus Vaccine for the Elderly Sales YoY (2020-2031) & (Dose)
Figure 63. Central and South America Respiratory Syncytial Virus Vaccine for the Elderly Revenue YoY (2020-2031) & (US$ Million)
Figure 64. Central and South America Top 5 Manufacturers Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) in 2024
Figure 65. Central and South America Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume (Dose) by Type (2021-2031)
Figure 66. Central and South America Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) by Type (2020-2031)
Figure 67. Central and South America Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume (Dose) by Application (2020-2031)
Figure 68. Central and South America Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) by Application (2020-2031)
Figure 69. Brazil Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2025) & (US$ Million)
Figure 70. Argentina Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2025) & (US$ Million)
Figure 71. Middle East, and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales YoY (2020-2031) & (Dose)
Figure 72. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue YoY (2020-2031) & (US$ Million)
Figure 73. Middle East and Africa Top 5 Manufacturers Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) in 2024
Figure 74. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume (Dose) by Type (2021-2031)
Figure 75. South America Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) by Type (2020-2031)
Figure 76. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume (Dose) by Application (2020-2031)
Figure 77. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) by Application (2020-2031)
Figure 78. GCC Countries Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2025) & (US$ Million)
Figure 79. Turkey Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2025) & (US$ Million)
Figure 80. Egypt Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2025) & (US$ Million)
Figure 81. South Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2025) & (US$ Million)
Figure 82. Respiratory Syncytial Virus Vaccine for the Elderly Industry Chain Mapping
Figure 83. Regional Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base Distribution (%)
Figure 84. Global Respiratory Syncytial Virus Vaccine for the Elderly Production Market Share by Region (2020-2031)
Figure 85. Respiratory Syncytial Virus Vaccine for the Elderly Production Process
Figure 86. Regional Respiratory Syncytial Virus Vaccine for the Elderly Production Cost Structure
Figure 87. Channels of Distribution (Direct Vs Distribution)
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed
Table 1. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Dose)
Table 7. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2020-2025) & (Dose)
Table 8. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2026-2031) & (Dose)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Manufacturers (2020-2025) & (Dose)
Table 11. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Share by Manufacturers (2020-2025)
Table 12. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Respiratory Syncytial Virus Vaccine for the Elderly by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Syncytial Virus Vaccine for the Elderly as of 2024)
Table 16. Global Respiratory Syncytial Virus Vaccine for the Elderly Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Respiratory Syncytial Virus Vaccine for the Elderly Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Dose)
Table 18. Key Manufacturers Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base and Headquarters
Table 19. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2020-2025) & (Dose)
Table 23. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2026-2031) & (Dose)
Table 24. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Respiratory Syncytial Virus Vaccine for the Elderly ASP by Type (2020-2031) & (US$/Dose)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2020-2025) & (Dose)
Table 29. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2026-2031) & (Dose)
Table 30. Respiratory Syncytial Virus Vaccine for the Elderly High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Respiratory Syncytial Virus Vaccine for the Elderly ASP by Application (2020-2031) & (US$/Dose)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Respiratory Syncytial Virus Vaccine for the Elderly Growth Accelerators and Market Barriers
Table 37. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Respiratory Syncytial Virus Vaccine for the Elderly Growth Accelerators and Market Barriers
Table 40. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Growth Accelerators and Market Barriers
Table 45. Southeast Asia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Respiratory Syncytial Virus Vaccine for the Elderly Investment Opportunities and Key Challenges
Table 47. Central and South America Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. GSK Corporation Information
Table 51. GSK Description and Major Businesses
Table 52. GSK Product Models, Descriptions and Specifications
Table 53. GSK Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 54. GSK Sales Value Proportion by Product in 2024
Table 55. GSK Sales Value Proportion by Application in 2024
Table 56. GSK Sales Value Proportion by Geographic Area in 2024
Table 57. GSK Respiratory Syncytial Virus Vaccine for the Elderly SWOT Analysis
Table 58. GSK Recent Developments
Table 59. Pfizer Corporation Information
Table 60. Pfizer Description and Major Businesses
Table 61. Pfizer Product Models, Descriptions and Specifications
Table 62. Pfizer Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 63. Pfizer Sales Value Proportion by Product in 2024
Table 64. Pfizer Sales Value Proportion by Application in 2024
Table 65. Pfizer Sales Value Proportion by Geographic Area in 2024
Table 66. Pfizer Respiratory Syncytial Virus Vaccine for the Elderly SWOT Analysis
Table 67. Pfizer Recent Developments
Table 68. Moderna Corporation Information
Table 69. Moderna Description and Major Businesses
Table 70. Moderna Product Models, Descriptions and Specifications
Table 71. Moderna Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 72. Moderna Sales Value Proportion by Product in 2024
Table 73. Moderna Sales Value Proportion by Application in 2024
Table 74. Moderna Sales Value Proportion by Geographic Area in 2024
Table 75. Moderna Respiratory Syncytial Virus Vaccine for the Elderly SWOT Analysis
Table 76. Moderna Recent Developments
Table 77. Daiichi Sankyo Corporation Information
Table 78. Daiichi Sankyo Description and Major Businesses
Table 79. Daiichi Sankyo Product Models, Descriptions and Specifications
Table 80. Daiichi Sankyo Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 81. Daiichi Sankyo Sales Value Proportion by Product in 2024
Table 82. Daiichi Sankyo Sales Value Proportion by Application in 2024
Table 83. Daiichi Sankyo Sales Value Proportion by Geographic Area in 2024
Table 84. Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly SWOT Analysis
Table 85. Daiichi Sankyo Recent Developments
Table 86. Icosavax Corporation Information
Table 87. Icosavax Description and Major Businesses
Table 88. Icosavax Product Models, Descriptions and Specifications
Table 89. Icosavax Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 90. Icosavax Sales Value Proportion by Product in 2024
Table 91. Icosavax Sales Value Proportion by Application in 2024
Table 92. Icosavax Sales Value Proportion by Geographic Area in 2024
Table 93. Icosavax Respiratory Syncytial Virus Vaccine for the Elderly SWOT Analysis
Table 94. Icosavax Recent Developments
Table 95. Sanofi Corporation Information
Table 96. Sanofi Description and Major Businesses
Table 97. Sanofi Product Models, Descriptions and Specifications
Table 98. Sanofi Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 99. Sanofi Recent Developments
Table 100. Blue Lake Biotechnology Corporation Information
Table 101. Blue Lake Biotechnology Description and Major Businesses
Table 102. Blue Lake Biotechnology Product Models, Descriptions and Specifications
Table 103. Blue Lake Biotechnology Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 104. Blue Lake Biotechnology Recent Developments
Table 105. Advaccine Corporation Information
Table 106. Advaccine Description and Major Businesses
Table 107. Advaccine Product Models, Descriptions and Specifications
Table 108. Advaccine Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 109. Advaccine Recent Developments
Table 110. Starna Therapeutics Corporation Information
Table 111. Starna Therapeutics Description and Major Businesses
Table 112. Starna Therapeutics Product Models, Descriptions and Specifications
Table 113. Starna Therapeutics Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 114. Starna Therapeutics Recent Developments
Table 115. Immorna Corporation Information
Table 116. Immorna Description and Major Businesses
Table 117. Immorna Product Models, Descriptions and Specifications
Table 118. Immorna Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 119. Immorna Recent Developments
Table 120. Clover Biopharma Corporation Information
Table 121. Clover Biopharma Description and Major Businesses
Table 122. Clover Biopharma Product Models, Descriptions and Specifications
Table 123. Clover Biopharma Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 124. Clover Biopharma Recent Developments
Table 125. Innorna Corporation Information
Table 126. Innorna Description and Major Businesses
Table 127. Innorna Product Models, Descriptions and Specifications
Table 128. Innorna Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 129. Innorna Recent Developments
Table 130. RNAimmune Corporation Information
Table 131. RNAimmune Description and Major Businesses
Table 132. RNAimmune Product Models, Descriptions and Specifications
Table 133. RNAimmune Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 134. RNAimmune Recent Developments
Table 135. Key Raw Materials Distribution
Table 136. Raw Materials Key Suppliers
Table 137. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 138. Milestones in Production Technology Evolution
Table 139. Distributors List
Table 140. Market Trends and Market Evolution
Table 141. Market Drivers and Opportunities
Table 142. Market Challenges, Risks, and Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Respiratory Syncytial Virus Vaccine for the Elderly Product Picture
Figure 2. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Recombinant Protein Vaccine Product Picture
Figure 4. Nucleic Acid Vaccines Product Picture
Figure 5. Others Product Picture
Figure 6. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Hospital
Figure 8. Centers for Disease Control and Prevention
Figure 9. Others
Figure 10. Respiratory Syncytial Virus Vaccine for the Elderly Report Years Considered
Figure 11. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 13. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Region (2020-2031)
Figure 15. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (2020-2031) & (Dose)
Figure 16. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (CAGR) by Region (2020-2031) (Dose)
Figure 17. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Region (2020-2031)
Figure 18. Top 5 and Top 10 Manufacturers Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume Market Share in 2024
Figure 19. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. Recombinant Protein Vaccine Revenue Market Share by Manufacturer in 2024
Figure 22. Nucleic Acid Vaccines Revenue Market Share by Manufacturer in 2024
Figure 23. Others Revenue Market Share by Manufacturer in 2024
Figure 24. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2020-2031)
Figure 25. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2020-2031)
Figure 26. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2020-2031)
Figure 27. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application (2020-2031)
Figure 28. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales YoY (2020-2031) & (Dose)
Figure 29. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue YoY (2020-2031) & (US$ Million)
Figure 30. North America Top 5 Manufacturers Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) in 2024
Figure 31. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume (Dose) by Type (2020- 2031)
Figure 32. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 33. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume (Dose) by Application (2020-2031)
Figure 34. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) by Application (2020-2031)
Figure 35. US Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 36. Canada Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 37. Mexico Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 38. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales YoY (2020-2031) & (Dose)
Figure 39. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Europe Top 5 Manufacturers Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) in 2024
Figure 41. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume (Dose) by Type (2020-2031)
Figure 42. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) by Type (2020-2031)
Figure 43. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume (Dose) by Application (2020-2031)
Figure 44. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) by Application (2020-2031)
Figure 45. Germany Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 46. France Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 47. U.K. Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 48. Italy Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 49. Russia Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales YoY (2020-2031) & (Dose)
Figure 51. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Asia-Pacific Top 8 Manufacturers Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) in 2024
Figure 53. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume (Dose) by Type (2020- 2031)
Figure 54. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 55. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume (Dose) by Application (2020-2031)
Figure 56. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) by Application (2020-2031)
Figure 57. Indonesia Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 58. Japan Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 59. South Korea Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 60. China Taiwan Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 61. India Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031) & (US$ Million)
Figure 62. Central and South America Respiratory Syncytial Virus Vaccine for the Elderly Sales YoY (2020-2031) & (Dose)
Figure 63. Central and South America Respiratory Syncytial Virus Vaccine for the Elderly Revenue YoY (2020-2031) & (US$ Million)
Figure 64. Central and South America Top 5 Manufacturers Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) in 2024
Figure 65. Central and South America Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume (Dose) by Type (2021-2031)
Figure 66. Central and South America Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) by Type (2020-2031)
Figure 67. Central and South America Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume (Dose) by Application (2020-2031)
Figure 68. Central and South America Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) by Application (2020-2031)
Figure 69. Brazil Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2025) & (US$ Million)
Figure 70. Argentina Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2025) & (US$ Million)
Figure 71. Middle East, and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales YoY (2020-2031) & (Dose)
Figure 72. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue YoY (2020-2031) & (US$ Million)
Figure 73. Middle East and Africa Top 5 Manufacturers Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) in 2024
Figure 74. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume (Dose) by Type (2021-2031)
Figure 75. South America Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) by Type (2020-2031)
Figure 76. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Volume (Dose) by Application (2020-2031)
Figure 77. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Revenue (US$ Million) by Application (2020-2031)
Figure 78. GCC Countries Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2025) & (US$ Million)
Figure 79. Turkey Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2025) & (US$ Million)
Figure 80. Egypt Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2025) & (US$ Million)
Figure 81. South Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2025) & (US$ Million)
Figure 82. Respiratory Syncytial Virus Vaccine for the Elderly Industry Chain Mapping
Figure 83. Regional Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base Distribution (%)
Figure 84. Global Respiratory Syncytial Virus Vaccine for the Elderly Production Market Share by Region (2020-2031)
Figure 85. Respiratory Syncytial Virus Vaccine for the Elderly Production Process
Figure 86. Regional Respiratory Syncytial Virus Vaccine for the Elderly Production Cost Structure
Figure 87. Channels of Distribution (Direct Vs Distribution)
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global UV Delayed Curing Adhesives Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Die-Casting Die Steel Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Adaptive Neuromodulation Therapy Devices Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232